Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004–2014

BACKGROUND: This study analyzes the pattern of use of single agent anticancer therapy (SAACT) in the treatment and survival of advanced hepatocellular carcinoma (aHCC) before and after sorafenib was FDA approved in 2007. METHODS: Adult patients diagnosed with HCC and treated with only ACT from 2004...

Descripción completa

Detalles Bibliográficos
Autores principales: Opneja, Aman, Cioffi, Gino, Alahmadi, Asrar, Jones, Nelroy, Tang, Tin‐Yun, Patil, Nirav, Bajor, David L., Saltzman, Joel N., Mohamed, Amr, Selfridge, Eva, Mangla, Ankit, Barnholtz‐Sloan, Jill, Lee, Richard T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267126/
https://www.ncbi.nlm.nih.gov/pubmed/34060249
http://dx.doi.org/10.1002/cam4.3985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267126/
https://www.ncbi.nlm.nih.gov/pubmed/34060249
http://dx.doi.org/10.1002/cam4.3985

Ejemplares similares